Post-translational modifications of some cell surface molecules that are radically different in transformed compared to normal tissue (e.g., tumour-associated glycoforms of MUC1) may offer an interesting alternative direction to the identification of safer targets for solid tumour CAR T-cell immunotherapy. This evidence concerns the gene MUC1 and neoplasm.